S1826 clinical trial for advanced Hodgkin lymphoma

• Amanda Bridges
• June 14, 2023
• Diversity & Inclusion

Accrual of the S1826 clinical trial for advanced Hodgkin lymphoma will likely shift treatment modality. Remarkable was the diversity reported for the collaborative study for the first time of the adult and pediatric cooperative research groups.It was the largest Hodgkin lymphoma trial conducted by the National Clinical Trials Network (NCTN) with a highly representative group: one-quarter were younger than 18, 10 percent were older than 60, one-quarter were Black or Hispanic, and higher-risk clinical subgroups were well represented.

The randomized phase III trial compared nivolumab plus the AVD combination (doxorubicin/Adriamycin, vinblastine, and dacarbazine) to a current standard treatment of brentuximab vedotin plus AVD.The nivolumab plus AVD (N-AVD) treatment cut patients’ risk of progression or death in half compared to the control arm treatment. The data showed 1-year PFS of 94 percent on the nivolumab arm versus 86 percent on the brentuximab vedotin arm. Overall, patients tolerated the N-AVD treatment better than the BV-AVD.